Compare Mesoblast Limited (MESO) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Monolithic Power Systems Inc — how do they compare? Mesoblast Limited trades at $16.23 (market cap $2.17B), while Monolithic Power Systems Inc trades at $1,373.93 (market cap $65.28B). The key difference: Monolithic Power Systems Inc is far larger — about 30.1× Mesoblast Limited's market cap, and Monolithic Power Systems Inc pays a 0.6% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MPWR | |
|---|---|---|
Market Cap | $2.17B | $65.28B |
Sector | Technology | Utilities |
52-Week High | $20.96 | $1.69K |
52-Week Low | $12.88 | $711.24 |
Enterprise Value | $2.17B | $63.94B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
MPWR trades at $1,328.80, up 1.28% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 22.98% net margin and robust cash flow, but carries high valuation multiples like a P/E of 93.92. Analyst consensus is overwhelmingly bullish with an $1,810 price target, though news includes both AI infrastructure optimism and legal investigations.
Outlook remains positive given earnings momentum and AI-driven demand, but risks include stretched valuations and ongoing legal scrutiny. The stock offers growth exposure but requires monitoring of execution and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
